Company profile: Memo Therapeutics
1.1 - Company Overview
Company description
- Provider of antibody discovery and immune repertoire analysis, featuring the MemoMAB platform to create and bank recombinant copies of individual B cell/antibody repertoires for high-throughput functional screening to identify potent, ultra-rare antibodies. Offers human antibody repertoire libraries, discovery in humans and rabbits, and AntiBKV for BK virus in kidney transplant recipients.
Products and services
- MemoMAB Technology Platform: High-throughput system that creates recombinant in vitro copies of individual B cell/antibody repertoires, banks them as libraries, and performs functional screening to detect potent, ultra-rare antibodies
- Human Antibody Repertoire Libraries: Clinically selected collections from human donors that capture unique, large and relevant immune repertoires for diverse antibody or target discovery projects, reflecting each individual’s antibody landscape
- Antibody Discovery in Humans: Human-sourced service that utilizes human sources for therapeutic antibody candidates, enhancing clinical success chances
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Memo Therapeutics
Hibiskus Bio
HQ: United States
Website
- Description: Provider of early-stage development of TIR-199, a small-molecule cancer therapy and potent proteasome inhibitor from the syrbactin natural product family, discovered by founders Profs. Pirrung and Bachmann of the University of California, Riverside (UCR) and Michigan.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hibiskus Bio company profile →
Valo Therapeutics
HQ: Finland
Website
- Description: Provider of immuno-oncology platforms developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. Offerings include PeptiCRAd (oncolytic adenoviruses plus tumor-specific peptides), PeptiENV (oncolytic enveloped viruses with peptides), PeptiVAX (peptide-based cancer vaccines), PeptiBAC (bacteria delivering tumor peptides), and PeptiCHIP (microchip-based tumor neoantigen identification).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valo Therapeutics company profile →
Kedrion Biopharma
HQ: United States
Website
- Description: Provider of plasma-derived medicinal products—clotting factors, albumin, and immunoglobulins—for treating hemophilia and immune deficiencies. Offers contract fractionation/manufacturing, technology transfer to build local plasma collection and fractionation, BioSC virus/prion safety studies (PCR, contaminants in cell cultures, in vitro, protein characterization), and pharmacovigilance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kedrion Biopharma company profile →
Sutro Biopharma
HQ: United States
Website
- Description: Provider of protein therapeutics leveraging OCFS and XpressCF cell-free protein synthesis, with an ADC pipeline: luveltamab tazevibulin (luvelta) targeting folate receptor alpha in clinical studies for platinum-resistant ovarian cancer; STRO-003 (ROR1-targeting) under a global licensing agreement with potential milestones and royalties; STRO-004 (tissue factor-targeting) planned for 2025 IND; plus sustainability efforts and a summer internship program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sutro Biopharma company profile →
Crescendo Biologics
HQ: United Kingdom
Website
- Description: Provider of Humabody VH-based antibody therapeutics and a discovery platform enabling rapid discovery of fully human VH domains for small, stable multi-specifics. Offerings include CB307 (PSMA x CD137 bispecific in trial for metastatic castration-resistant prostate cancer), CB213 (preclinical PD-1 x LAG-3), and ZL-1102 (topical IL-17A; licensed to Zai Lab). Also engages in partnered and licensed programs with BioNTech, Takeda.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crescendo Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Memo Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Memo Therapeutics
2.2 - Growth funds investing in similar companies to Memo Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Memo Therapeutics
4.2 - Public trading comparable groups for Memo Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →